Choroidal Neovascularization Market Outlook Signals Expansion To $5.98 Billion Through 2030

The choroidal neovascularization market is on track for considerable expansion as we approach 2030. Advances in treatment options and rising awareness of eye health are setting the stage for strong growth in this specialized ophthalmic sector. Let us explore the projected market size, key players, emerging trends, and detailed segment insights shaping this industry.

Forecasted Growth and Market Size of the Choroidal Neovascularization Market
The global choroidal neovascularization market is projected to reach a valuation of $5.99 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.4%. This expansion is driven by several factors, including the aging global population and the increasing emphasis on early ophthalmic interventions. Additionally, the adoption of combination therapies, rising investments in retinal disease research, and growing use of personalized treatment regimens contribute to this upward trajectory. Key trends anticipated to influence the market include greater use of anti-VEGF therapies, the growing preference for treat-and-extend dosing schedules, advancements in early CNV diagnosis, wider application of sophisticated retinal imaging technologies, and a stronger focus on therapies aimed at preserving vision.

The choroidal neovascularization market size has grown strongly in recent years. It will grow from $4.18 billion in 2025 to $4.5 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increasing prevalence of age-related macular degeneration, rising diabetic eye disease cases, expansion of ophthalmology clinics, availability of anti-angiogenic drugs, improved retinal diagnostic capabilities.

Download a free sample of the choroidal neovascularization market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Factors Accelerating Growth in the Choroidal Neovascularization Market
A primary driver of market growth is the rising number of elderly individuals worldwide, who are more susceptible to retinal conditions such as choroidal neovascularization. This demographic shift creates a heightened demand for effective eye care solutions.
Moreover, healthcare providers and researchers are increasingly prioritizing early detection and intervention strategies. This focus leads to broader adoption of innovative diagnostic tools and treatment protocols, enhancing patient outcomes and fostering market expansion.

Top Companies Leading the Choroidal Neovascularization Industry
The market features several key players actively shaping its landscape, including Roche Holding AG, Regeneron Pharmaceuticals Incorporated, Bayer Aktiengesellschaft, Novartis AG, Apellis Pharmaceuticals Incorporated, Kodiak Sciences Incorporated, Adverum Biotechnologies Incorporated, Clearside Biomedical Incorporated, Graybug Vision Incorporated, Outlook Therapeutics Incorporated, Oxurion NV, 4D Molecular Therapeutics Incorporated, Opthea Limited, Eyepoint Pharmaceuticals Incorporated, Ocular Therapeutix Incorporated, OcuTerra Therapeutics Incorporated, Ocuphire Pharma Incorporated, Kubota Vision Incorporated, Amgen Incorporated, Coherus BioSciences Incorporated, Formycon AG, Alimera Sciences Incorporated, Neurotech Pharmaceuticals Incorporated, Alkeus Pharmaceuticals Incorporated, Aerie Pharmaceuticals Incorporated, and Acucela Incorporated.
In a notable recent development, Switzerland-based Sandoz Group AG acquired the CIMERLI business from Coherus BioSciences for $170 million in March 2024. This acquisition is aimed at boosting Sandoz's ophthalmic portfolio, particularly in delivering innovative retinal disease treatments such as those for age-related macular degeneration (AMD). Coherus BioSciences, based in the United States, is recognized for its focus on research and development in retinal diseases including choroidal neovascularization.

View the full choroidal neovascularization market report:
https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends Steering the Choroidal Neovascularization Market
Leading companies are investing heavily in the development of new therapies designed to enhance treatment precision and patient outcomes. One such innovation is photodynamic therapy (PDT), which uses light-activated agents to selectively destroy abnormal cells.
For example, in February 2023, Bausch & Lomb, a Canadian healthcare firm, partnered with Finland-based Modulight to introduce the ML6710i photodynamic laser, which received FDA approval. This advanced, portable laser system is designed for use alongside Bausch & Lomb's VISUDYNE therapy and targets abnormal blood vessels in the eye caused by AMD-related choroidal neovascularization. Such technological advances offer more targeted and effective treatment options while helping to preserve patients' vision.

Detailed Segment Breakdown of the Choroidal Neovascularization Market
The market can be divided into several critical segments:
1) Treatment Type: The therapies include Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, and Pegaptanib Sodium.
2) Indication: The conditions treated encompass Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), and other related disorders.
3) Route of Administration: Treatments are delivered through Intravitreal, Subconjunctival, Periocular, and Oral pathways.
4) End User: Key end users include Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, and Research Centers.

Further subsegment classifications offer precise insights, such as:
- Anti-Angiogenic Therapy broken down into Ranibizumab, Bevacizumab, Aflibercept, and Pegaptanib Sodium
- Laser Photocoagulation divided into Thermal Laser and MicroPulse Laser therapies
- Photodynamic Therapy detailed into Standard, Low-Fluence, and Half-Dose PDT
- Verteporfin Sodium categorized by Intravenous administration and combination therapy with Anti-VEGF agents
- Ranibizumab usage segmented by Monthly dosing, As-needed dosing, and Treat-and-Extend regimens
- Bevacizumab differentiated by off-label use and compounded intravitreal injections
- Aflibercept regimens split into fixed dosing and treat-and-extend strategies
- Pegaptanib Sodium usage classified into monotherapy and combination therapy.

This comprehensive segmentation provides a clear framework for understanding the different facets of the choroidal neovascularization market and its evolving therapeutic landscape.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.